Clinical Failures Persist Because They’re Structural, Not Random

Author(s): Mikhail Evteev

When Bayer’s Factor XIa program failed, it may have ended a single asset, but it also triggered a reassessment of an entire therapeutic strategy. Factor XIa inhibition had been positioned as a next-generation anticoagulation approach, promising efficacy without the bleeding risks associated with existing therapies. Early data across multiple sponsors supported that narrative. Programs scaled quickly into large, expensive cardiovascular outcome trials. They failed.

In turn, sponsors paused development, investors repriced the entire class, and competing programs were forced to reevaluate their assumptions. Clinical failures are no longer contained within a single program; they propagate across portfolios, companies, and therapeutic areas, influencing regulatory interpretation, capital allocation, and trial design. The relevant question is no longer why a specific trial failed but why similar failures continue to emerge across different programs and disease areas.